AVTX
Avalo Therapeutics Inc
NASDAQ: AVTX · HEALTHCARE · BIOTECHNOLOGY
$13.20
+2.64% today
Updated 2026-04-29
Market cap
$317.21M
P/E ratio
—
P/S ratio
5,376.53x
EPS (TTM)
$-5.84
Dividend yield
—
52W range
$3 – $21
Volume
0.8M
Avalo Therapeutics Inc (AVTX) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
-33,461.00%
ROE
-72.40%
ROA
-34.10%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2012 | $82760.00 | $-10.49M | -10,142.39% | -12,676.35% | -12,674.72% |
| 2013 | — | $-13.05M | — | — | — |
| 2014 | — | $-16.06M | — | — | — |
| 2015 | — | $-10.49M | — | — | — |
| 2016 | $1.15M | $-16.47M | -614.57% | -1,394.62% | -1,428.53% |
| 2017 | $27.81M | $11.87M | 97.71% | 49.94% | 42.68% |
| 2018 | $18.33M | $-40.05M | 59.19% | -214.52% | -218.55% |
| 2019 | $6.75M | $-16.07M | 108.39% | -239.06% | -238.10% |
| 2020 | $6.70M | $-63.50M | 95.52% | -402.34% | -947.90% |
| 2021 | $5.40M | $-84.38M | 72.38% | -1,521.56% | -1,563.10% |
| 2022 | $18.05M | $-41.66M | 80.98% | -207.41% | -230.78% |
| 2023 | $1.92M | $-31.54M | 33.26% | -1,421.57% | -1,639.50% |
| 2024 | $441000.00 | $-35.13M | 182.99% | -15,535.60% | -7,965.76% |
| 2025 | $59000.00 | $-78.26M | -483.05% | -123,601.69% | -132,642.37% |